Posts
Est. 2026 · Pennsylvania
The Word
Donation
How a Single Term Carries the Weight of an Industry
The FDA distinguishes between paid and volunteer donors for blood intended for transfusion. It does not apply that distinction to source plasma. The industry calls compensated collection "donation." This is not an accident of terminology. It is the most important word in the architecture.
Words do work. In a system of this scale — a global supply chain generating tens of billions of dollars annually, built on the bodies of low-income Americans — the word that describes the transaction at the source layer is not a neutral administrative choice. It is the foundation of the system's legitimacy.
The word is donation. The industry uses it. The FDA permits it. Collection centers are called donation centers. The people who sell their plasma are called donors. The compensation they receive is framed as payment for their time, not for the plasma itself — a distinction without practical meaning but with considerable legal and ethical function.
This post maps that word — where it came from, what it does, what it conceals, and why the distinction between "paid" and "volunteer" was carefully applied to one category of blood product and carefully not applied to another.
The voluntary transfer of something without compensation. A gift. An act of giving in which the giver receives nothing of material value in return.
The transfer of source plasma to a licensed collection center in exchange for monetary compensation of $30–$70 or more per session, up to 104 times per calendar year, at facilities deliberately sited in high-poverty census tracts, by a donor base that is predominantly low-income and economically motivated.
Load-bearing insulation. A term whose standard meaning provides ethical cover for a transaction whose actual structure that meaning does not describe. The gap between the two is not incidental. It is the point.
The paid/volunteer distinction in American blood banking is not new. It has a history, a crisis, and a legislative response. Understanding where the distinction came from clarifies why it was applied where it was — and why it was not applied to source plasma.
In the late 1960s and early 1970s, hepatitis B transmission through transfused blood was a documented public health problem. Paid whole-blood donors — people who sold blood for direct transfusion — had measurably higher rates of hepatitis than volunteer donors. The economic incentive to donate frequently, combined with inadequate screening, produced a contaminated supply. Patients received transfusions and contracted hepatitis. The evidence was clear enough that hospitals began to shift away from paid whole blood, and in 1978 the FDA moved to require labeling: containers of blood for transfusion must state whether the source was a "paid donor" or a "volunteer donor."
The effect was decisive. Hospitals preferred volunteer-labeled blood. Paid whole blood for transfusion effectively disappeared from the American market. The terminology did its regulatory work — not through prohibition, but through disclosure that made the paid product commercially unviable in the institutional market.
The labeling requirement did not ban paid whole blood. It made hospitals choose. Hospitals chose volunteer. The market enforced what the regulation only disclosed.
The 1978 labeling regulation that effectively ended paid whole blood for transfusion contained an exception: it applied to blood and blood components intended for direct transfusion. It did not apply to source plasma collected for further manufacturing into plasma-derived medicinal products.
The regulatory logic was defensible. The safety concern was transmission risk in transfused products — hepatitis passing directly from donor to patient through a single unit of blood. Source plasma undergoes extensive processing: pooling of thousands of donations, fractionation, heat treatment, solvent-detergent pathogen inactivation, viral filtration. The manufacturing process itself addresses transmission risks in ways that single-unit transfusion cannot. The safety argument for treating source plasma differently from whole blood for transfusion was not baseless.
But the exception had consequences beyond safety. It created a category — source plasma — in which paid collection was not only permitted but normalized, in which the market infrastructure for high-frequency paid donation could be built at scale, and in which the industry-wide terminology of "donation" could be maintained despite the transactional reality. The exception was not designed to build a global supply monopoly. But the exception is what made one possible.
The terminology architecture of "donation" performs at least four distinct functions simultaneously. Each function addresses a different audience. Together, they constitute the insulation layer of the blood economy.
For donors: "Donation" frames the transaction as an act of social good. The donor is not a seller — they are a contributor. The compensation is for their time. They are helping patients. This framing makes participation feel morally coherent even to donors who are primarily motivated by economic need. It is not a lie — plasma does save lives. But it is a frame, and frames shape behavior.
For regulators: "Donation" keeps source plasma within a regulatory tradition built around gift-giving and altruism, which has its own established ethics and legal frameworks. Calling it a "sale" would invite different regulatory analysis — commodity markets, labor law, consumer protection. The terminology preserves regulatory continuity.
For importing nations: "Donation" provides diplomatic cover. European countries whose official policy prohibits paid plasma can import medicines derived from paid American plasma without formally endorsing the practice. The product they import is made from "donations." The ethical contradiction is insulated by terminology.
For the industry: "Donation" shields against commodification critique. A market in which human plasma is openly bought and sold faces political and public relations pressure that a system of "compensated donation" does not. The distinction is not recognized in law for source plasma — but it is recognized in public perception, and public perception is part of the insulation layer.
The most precise piece of the insulation architecture is the framing of payment as compensation for time rather than for plasma. This distinction has no biological basis and no economic logic — but it has considerable legal and rhetorical function.
Biologically: a collection center does not want the donor's time. It wants the donor's plasma. If a donor spent an hour in the center chair and the apheresis machine failed to extract plasma, no payment would be issued. The time has no value to the center without the plasma. The transaction is for plasma. The framing that it is for time is precisely that: a framing.
Economically: payment rates vary by volume of plasma collected, which varies by donor weight. Larger donors who yield more plasma are paid more. This is a volume-based pricing structure. It is not compensation for time spent. It is compensation for units produced — which is, straightforwardly, the structure of a purchase.
Legally: calling payment compensation for time rather than for plasma keeps the transaction outside the regulatory frameworks that govern commodity sales. Plasma as a purchased commodity would raise questions about labor classification, commodity market regulation, and consumer protection law that plasma as "compensated donation" does not.
The compensation-for-time framing is not a legal finding. It is an industry convention that regulators have accepted and codified through inaction. No court has formally ruled that source plasma collection is not a purchase. The framing has persisted because it benefits every party with regulatory influence: the industry, which avoids commodity classification; the FDA, which avoids regulatory expansion; and importing nations, which avoid ethical contradiction. The donor, who has no regulatory voice, is the only party for whom the framing provides no benefit.
The word "donation" is not a fraud. It is not a conspiracy. It is something more structurally interesting: a term whose standard meaning has been quietly hollowed out and replaced with a market transaction, while the ethical resonance of the original meaning is preserved and deployed as insulation.
The 1970s regulatory history that created the source plasma exception was driven by legitimate safety reasoning. The decision to apply "paid/volunteer" labeling only to transfusion blood — not to plasma for manufacturing — was defensible on safety grounds. But it had a second-order consequence: it created the regulatory space in which an industry could normalize paid collection under a voluntary framework, build a global supply monopoly, and sustain that monopoly against ethical challenge through terminology that its own regulatory history had made difficult to dislodge.
Post III will move from language to geography. The word "voluntary" suggests freedom from compulsion. The map of where collection centers are built tells a different story.
Next · Post III · The Siting Decision — Poverty geography, census tract data, and the deliberate logic of locating extraction near need.
